Global HTA Strategy And Dossier Development

The following discussion illustrates a project that is well suited to the capabilities of an independent consultant in the Umbrex Biotechnology Practice. This is an illustrative example. Umbrex consultants adapt their methodology, timeline, and deliverables to the specific needs of each client.

1) Client Situation

The client operated within the therapeutics-focused biotech ecosystem and required support with Global HTA Strategy And Dossier Development in the context of Biotechnology. Teams across Emerging Therapeutic Biotech (Preclinical), Clinical-Stage Biotech (Phase I–III), Commercial Biotech (Post-Approval), Platform Biotech (Therapeutic Discovery), and Biotech Investors & Incubators asked for an integrated approach to develop a Global Value Dossier (GVD) and AMCP dossier, plan country HTA submissions (NICE, G-BA/IQWiG under AMNOG, SMC, HAS, and other priority agencies), and tailor evidence and narratives to maximize first-cycle approval probability. The diagnostic we conducted surfaced concrete gaps that threatened timelines, price, and access breadth:

• Fragmented value narrative and comparator alignment. Clinical and HEOR materials did not translate the Target Product Profile into payer/HTA language across markets. Appropriate comparator therapy (ZVT) for G-BA was not aligned with comparators expected by NICE, SMC, and HAS. Evidence against generics/biosimilars and lowest-net alternatives required by payers was not explicitly addressed.
• Evidence incompleteness vs. HTA expectations. Endpoints favored regulators but not HTA decision criteria (e.g., lack of validated utilities, limited HRU capture, sparse adherence/persistence data). Indirect treatment comparisons were not planned or were methodologically weak (insufficient matching/anchoring). Survival extrapolation strategies and scenario analyses needed country-specific calibration.
• Economic models not “HTA-grade.” Global economic models lacked transparent assumption books, localizable inputs, and validation histories. EQ-5D evidence and mapping strategies for utilities were incomplete; costing frameworks did not reflect country tariffs, treatment pathways, or discounting conventions.
• Country submission pathways unclear. AMNOG milestones (Dossier Module 4 evidence, G-BA timelines, price negotiation sequencing) were not mapped; NICE scoping and severity modifier implications were unaddressed; SMC New Product Assessment vs. ultra-orphan criteria were not evaluated; HAS SMR/ASMR drivers and post-listing study expectations were not planned.
• Pricing corridors and ICER targets not reconciled. Proposed WAC/net price corridors were not tested against inferred willingness-to-pay thresholds and price–volume dynamics by country. Contracting guardrails did not reflect managed entry agreements (MEAs), data collection, or outcome-based schemes commonly requested by HTAs.
• Local affiliate readiness uneven. Country teams lacked aligned messages, submission templates, and Q&A libraries; timelines for translation, redaction, and local cost/clinical practice data collection were not synchronized with global milestones.
• AMCP dossier and PIE program underdeveloped. US payer materials did not incorporate credible ITC/NMA and budget impact scenarios; scientific exchange plans for pre-approval information exchange (PIE) were not operationalized, risking time-to-coverage post-approval.
• EU HTA regulation (Joint Clinical Assessment) not anticipated. Oncology/ATMP-relevant timelines and dossier harmonization were not built into narrative or evidence plans, creating a risk of divergent judgments across Member States.
• Stakeholder engagement gaps. Early advice with HTA bodies (NICE Scientific Advice, G-BA advice, HAS early dialogue, EUnetHTA JSC) was not scheduled; patient submission strategy and clinician KOL alignment were not integrated into the submission plan.
• Operational insufficiencies. Kaplan–Meier curves and IPD availability were unclear; real-world data partnerships were not finalized; coding/translation vendors lacked HTA experience; response management and hearing preparation playbooks were absent.

2) Project Objective

The primary objective focused on designing and executing a global HTA strategy and dossier program—developing a coherent Global Value Dossier and AMCP dossier; planning and tailoring NICE, G-BA, SMC, and HAS submissions; and aligning economic and clinical evidence to secure first-cycle, favorable HTA decisions and price negotiations.

Secondary objectives included:

• Aligning appropriate comparators and treatment pathways by country, including ZVT for G-BA, NICE scoping expectations, SMC comparator norms, and HAS practice patterns.
• Building defensible indirect comparisons (ITC/NMA, MAIC/STS as needed) and survival extrapolations; validating utilities and HRU inputs; and documenting sensitivity and scenario analyses per local guidance.
• Developing a global economic model with country adaptation packs (inputs, tariffs, discounting, perspective) and transparent assumption books for affiliates.
• Sequencing HTA milestones (scientific advice, dossier submissions, hearings, price negotiation windows, MEA options) with regulatory, pricing, and launch planning.
• Operationalizing AMCP dossier and PIE, synchronized with US coding, coverage, and distribution milestones.
• Embedding a country response engine (clarification responses, hearings, oral/written statements) and Q&A playbooks; training cross-functional teams.
• Defining a post-approval HEOR/RWE plan to support reassessments, renewals, and policy maintenance (registry/data collection, outcomes measurement for MEAs).

3) Methodology and Approach

Workstream 1: Global HTA Landscape and Strategy Definition

We set the strategic frame across priority markets and aligned internal stakeholders on positioning and trade-offs.

• Activities we conducted:
  • Mapped HTA processes, timelines, evidence standards, and pricing linkages for NICE, G-BA/IQWiG (AMNOG), SMC, HAS, and other target agencies; identified opportunities for early advice and parallel scientific consultation.
  • Defined country archetypes (cost-effectiveness driven vs. clinical/evidence-weighted vs. budget impact prioritization) and tailored value objectives and minimum access outcomes.
  • Aligned global comparator strategy; defined ZVT for Germany, NICE appropriate comparators under scoping, HAS practice comparators, SMC expectations; captured differences and mitigation plans.
• Tools and frameworks used: HTA milestones gantt, comparator alignment matrix, value objective and trade-off register, stakeholder governance charter.
• Stakeholders involved: global HEOR, clinical, regulatory, pricing/market access, country access leads, finance.

Workstream 2: Evidence Synthesis, ITC/NMA, and Clinical Narrative

We translated clinical data into country-ready narratives and robust indirect comparisons.

• Activities we conducted:
  • Built a consolidated evidence compendium (efficacy, safety, subgroups, HRQoL, adherence, persistence, HRU). Assessed feasibility of anchored and unanchored ITC/NMA; executed analyses (NMA, MAIC/STS) with sensitivity checks for heterogeneity and bias.
  • Developed survival models (parametric forms, mixture-cure, spline-based where appropriate); documented model selection criteria, external validation, and plausibility against RWD benchmarks.
  • Crafted the clinical value story: unmet need, patient journey, endpoint relevance, magnitude/durability of effect, benefit–risk; aligned to country templates (e.g., G-BA Module 4, NICE submission sections, HAS Transparency Committee expectations, SMC clinical effectiveness narrative).
• Tools and frameworks used: ITC/NMA analysis plan, survival extrapolation library, evidence strength rubric, clinical value storyline map.
• Stakeholders involved: biostatistics, HEOR, clinical, medical affairs, external methodologists/KOLs as needed.

Workstream 3: Global Economic Model and Country Adaptation Packs

We built decision-grade economic models with localizable inputs and transparent assumption books.

• Activities we conducted:
  • Developed a global cost-effectiveness model (CEM or partitioned survival model) anchored in trial/IPD data and ITC/NMA outputs; built a budget impact model (BIM) aligned with country incidence/prevalence, uptake, and cost structures.
  • Created country adaptation packs: perspectives (payer/NHS), discounting, time horizons, tariffs (NHS reference costs, HRG, DRG, Lauer-Taxe/EBM/GOÄ in Germany, CCAM/ENCC/ATIH in France), resource use patterns, utility sources (EQ-5D-3L/5L mapping), and currency/PPP assumptions.
  • Produced assumption books and validation logs (cross-checks with published models, external calibration to RWD), and scenario repositories for accelerated local adaptation and affiliate review.
• Tools and frameworks used: base model with version control, country input library, utility mapping catalog, model validation checklist, NICE/SMC technical checklist alignment tools.
• Stakeholders involved: HEOR/economics, biostatistics, country access leads, pricing, affiliates.

Workstream 4: Global Value Dossier (GVD) and AMCP Dossier Development

We created payer-ready core content and a US-specific dossier to support P&T decisions.

• Activities we conducted:
  • Authored the GVD (disease burden, clinical value, HRQoL, economic evidence, RWE compendium, references) per HTA Core Model; constructed country annexes with evidence alignment and gap mitigation plans.
  • Developed an AMCP dossier with payer-calibrated messaging, ITC/NMA summaries, BIM/CEM outputs, and transparent assumptions; prepared PIE-compliant pre-approval exchange materials.
  • Conducted medical-legal and affiliate reviews; implemented content management and version control for downstream submissions.
• Tools and frameworks used: GVD template aligned to HTA Core Model, AMCP dossier template, reference management, change log and affiliate feedback tracker.
• Stakeholders involved: HEOR, medical affairs, regulatory/MLR, US market access, affiliates.

Workstream 5: Country Submission Dossier Tailoring and Scientific Advice

We prepared country-specific dossiers and engaged in early advice to de-risk first-cycle outcomes.

• Activities we conducted:
  • NICE: drafted submission with scope alignment, severity modifier considerations, model technical support document (TSD)-aligned methods, and equality considerations; prepared for technical engagement and committee meeting.
  • G-BA/IQWiG: compiled AMNOG dossier with Module 3/4 evidence, benefit categories by patient-relevant endpoints, ZVT rationale, subgroup delineation, and hearing preparation materials.
  • HAS: tailored diagnosis/treatment pathway, clinical effectiveness narrative, SMR/ASMR case, and post-listing study readiness; aligned on CT label and economic context.
  • SMC: drafted New Product Assessment for clinical and economic submissions; evaluated FAST-TRACK criteria; prepared patient and clinician group submissions coordination.
  • Scheduled and executed scientific advice/early dialogues (NICE SA, G-BA, HAS, EUnetHTA JSC) to validate methods, comparators, and evidence plans; documented agency feedback and adjustments.
• Tools and frameworks used: country submission templates, question banks and response playbooks, hearing simulation scripts, early advice tracker.
• Stakeholders involved: affiliates, global HEOR, clinical, pricing, regulatory, external advisors.

Workstream 6: Pricing Strategy, MEAs, and Negotiation Readiness

We aligned price and contracting options with HTA positions and country negotiation dynamics.

• Activities we conducted:
  • Modeled price–volume and ICER sensitivity by country; tested net price corridors against inferred thresholds and budget impact norms; evaluated cross-country external reference pricing implications.
  • Designed managed entry agreement options (outcomes-based, data collection, discounts/rebates) consistent with local policy and measurement feasibility; built operational plans for data capture and evaluation.
  • Prepared negotiation dossiers with model outputs, scenario trees, and red-line/green-line guardrails; trained country teams for negotiation cycles and hearing dynamics.
• Tools and frameworks used: price–ICER simulator, MEA design catalog, negotiation playbooks, ERP risk register.
• Stakeholders involved: pricing/contracting, HEOR, affiliates, legal, supply.

Workstream 7: HTA Response Engine and Hearing Preparation

We built the processes and materials to respond to clarification questions and participate in hearings effectively.

• Activities we conducted:
  • Established a response engine: intake triage, evidence owners, modelers on-call, editorial controls, and sign-off cadence; created a repository of pre-approved responses, figures, and model outputs with version control.
  • Prepared oral/written statements for hearings (NICE committee, G-BA, HAS, SMC); ran simulations with cross-functional teams; aligned roles and pivot/bridging statements.
  • Documented decisions and evidence changes in a change log; ensured alignment with regulatory label and safety updates.
• Tools and frameworks used: response tracker, hearing rehearsal kits, message maps, figure/style guide for rapid turnarounds.
• Stakeholders involved: HEOR, clinical, pricing, affiliates, external advisors, communications.

Workstream 8: Post-Approval HEOR/RWE and Policy Maintenance

We set a roadmap to maintain and improve HTA positions over time.

• Activities we conducted:
  • Prioritized RWE (adherence/persistence, HRU, special populations, sequencing) to support renewals/reassessments; designed registry or claims partnerships and statistical analysis plans (target trial emulation where relevant).
  • Created a dossier refresh calendar; maintained a publication plan aligned to HTA cycles; instituted policy monitoring (threshold changes, severity modifiers, HAS ASMR guidance updates).
  • Planned governance for MEA performance tracking and reporting; aligned internal accountabilities and data strategies.
• Tools and frameworks used: evidence roadmap, policy monitoring dashboard, MEA governance SOPs.
• Stakeholders involved: HEOR/RWE, medical affairs, market access, affiliates, data partners.

Workstream 9: Affiliate Enablement and Training

We equipped country teams to execute submissions and negotiations consistently.

• Activities we conducted:
  • Delivered training on dossier content, model operation and scenario runs, ITC/NMA interpretation, and hearing conduct; localized value message decks and objection handlers.
  • Established a central–local collaboration model: content governance, query turnaround SLAs, translation/redaction workflows, and audit-ready documentation.
• Tools and frameworks used: affiliate playbooks, training modules, collaboration RACI, content repository with permissioning and version control.
• Stakeholders involved: affiliates, global HEOR/access, medical, regulatory.

Workstream 10: Program Governance and Risk Management

We instituted cadence, decision rights, and risk controls for the HTA program.

• Activities we conducted:
  • Set monthly HTA steering and biweekly operational reviews; maintained risk register (evidence, timelines, pricing, ERP, policy shifts) with mitigation owners.
  • Aligned cross-functional calendars (regulatory submissions, pricing decisions, manufacturing/COGS updates) to avoid conflicts with HTA claims and economics.
• Tools and frameworks used: program governance charter, risk register and mitigation tracker, integrated milestone plan.
• Stakeholders involved: HEOR/access leadership, clinical, regulatory, pricing, affiliates, finance.

4) Data Request

We requested datasets and artifacts necessary to build the GVD/AMCP dossier and country submissions. Typical horizons were current clinical/economic evidence and 12–24 months forward for launch and reassessment plans.

• Clinical efficacy and safety:
  • CSRs, SAPs, KM curves (IPD where available), subgroup results, PRO/HRQoL instruments and analyses, AE/SAE profiles, dose modifications, treatment discontinuations, adherence/persistence.
• Comparators and RWE:
  • Published comparator trials and IPD if accessible; real-world datasets (claims/EHR/registries) for HRU, persistence/adherence, dose escalation, and mortality; practice patterns and treatment sequencing by country.
• Economic inputs:
  • Utilities (EQ-5D-3L/5L, HUI, SF-6D), mapping algorithms, HRU frequencies, unit costs (tariffs, drug prices with ex-factory and distribution markups), productivity where permitted; discounting conventions and perspectives per country.
• Model artifacts:
  • Global CEM/PSM and BIM files, assumption books, validation logs, sensitivity/scenario sets; documentation of survival extrapolations and ITC/NMA methods.
• Country processes:
  • HTA calendars and templates (NICE, G-BA AMNOG, SMC, HAS), early advice history and feedback, submission deadlines, hearing requirements; translation and redaction workflows.
• Pricing/contracting:
  • WAC and net price corridors, ERP baskets, anticipated discount/rebate structures, MEA concepts, confidential price policy constraints, ERP risk by timing.
• US payer materials:
  • AMCP dossier drafts, PIE plans, budget impact scenarios, objection/response libraries; coding/reimbursement guides.
• Affiliate readiness:
  • Local epidemiology, tariffs, practice patterns, KOL and patient group contacts; affiliate resourcing and vendor plans for submissions and translations.

Common data pitfalls included inconsistent comparator definitions across markets, missing or non-validated utilities, limited HRU capture, insufficient documentation of survival extrapolation choices, incomplete model validation logs, lack of country-ready cost inputs, and unscheduled early advice windows. We established a data dictionary, assumption books, and a controlled content repository before drafting dossiers.

5) Questions for Client

• What are the non-negotiable value claims at launch (clinical magnitude, speed, durability, QoL) and how should they translate into country narratives?
• Which comparators must we prioritize by country (including ZVT for Germany), and where are we comfortable relying on ITC/NMA vs. head-to-head evidence?
• What price corridors and ICER targets are acceptable by market; where are MEAs feasible, and what outcomes or data collection are operationally realistic?
• Which early advice opportunities should we pursue (NICE, G-BA, HAS, EUnetHTA JSC), and what positions require validation or alignment?
• What RWE partnerships can we mobilize pre- and post-launch to address adherence, HRU, and special populations?
• How should we sequence submissions across countries relative to regulatory approval and ERP dynamics?
• What affiliate resourcing and vendor support exist for translation, redaction, and local data collection; what training is required?
• What hearing posture and spokespersons are preferred; who will own rapid response and change control during HTA reviews?
• How should the AMCP and PIE programs align with global value messaging, coding, and US access milestones?
• What governance cadence and decision rights will steer trade-offs between price, timing, and access breadth?

6) Interview Guide for Subject Matter Experts

Global HEOR / Value Evidence Lead

• Which endpoints and outcomes resonate most with HTAs; where do we have gaps or uncertainty?
• What ITC/NMA approaches are feasible; how do we manage heterogeneity and bias; what sensitivity analyses will be persuasive?
• What utilities and HRU sources are defensible; where do we need mapping or new evidence generation?

Biostatistics / Modeling Lead

• How will we structure survival extrapolations; what external validation will we use; how do we document model choice?
• What assumptions drive cost-effectiveness; how will we handle structural uncertainty and parameter uncertainty?
• What is the plan for model transparency, validation, and affiliate reproducibility?

Global/Regional Market Access and Pricing

• What price–ICER envelope is targeted by country; how do ERP and launch sequence influence corridors?
• Where are MEAs likely; what outcomes can be measured reliably; how do we operationalize data capture?
• What negotiation guardrails and decision rights apply at national and subnational levels?

Affiliate Access Leads (UK/DE/FR/Scotland)

• What comparators and practice patterns do local committees expect; what local data gaps exist?
• Which additional stakeholders (patient groups, clinician experts) should we involve; what hearing dynamics should we anticipate?
• What translation, redaction, and submission constraints affect timing?

Medical Affairs / Clinical

• What clinical narratives best frame unmet need and benefit–risk; how do we address uncertainty and subgroups?
• What clinician and patient insights can support submissions; how will we coordinate with patient group submissions?

US Payer Strategy / AMCP Owner

• Which messages and comparators drive P&T decisions; how should AMCP/PIE materials align with global evidence?
• What BIM assumptions are credible for major plans; how do we handle limitations transparently?

RWE / Data Partnerships

• Which datasets can support HRU, adherence, persistence, and special populations; what timelines and governance are tractable?
• How will we ensure data quality and comparability to trial cohorts?

Legal / Compliance

• What policies govern PIE, patient group interactions, and MEA confidentiality; what risks must be mitigated?
• How will we manage version control and documentation for audits and external requests?

7) Timeline

We executed a 12–14 week plan tailored to Global HTA Strategy & Dossier Development within Market Access & HEOR.

• Weeks 1–2: Diagnostic and Strategy Alignment
  • Assessed evidence, comparators, and HTA processes by country; aligned on value objectives, comparator choices, and early advice strategy; defined governance and milestone plan.
  • Decision Gate A: Approved global HTA strategy, comparator alignment, and early advice schedule; confirmed data access and modeling scope.
• Weeks 3–4: Evidence Synthesis and ITC/NMA
  • Built evidence compendium; executed ITC/NMA; drafted clinical narratives per country templates; scoped survival extrapolation strategies and validation approach.
  • Decision Gate B: Ratified clinical narratives and ITC/NMA methods/results; authorized global model build.
• Weeks 5–6: Economic Model Build and Country Adaptation Framework
  • Developed global CEM/PSM and BIM; prepared assumption books and validation logs; created country input libraries and adaptation guidance.
  • Decision Gate C: Approved model architecture and validation; authorized GVD and AMCP drafting; initiated affiliate data requests.
• Weeks 7–8: GVD/AMCP Drafting and Early Advice
  • Completed GVD and AMCP drafts; ran medical-legal review; conducted early advice sessions (where scheduled) and recorded feedback; updated comparators/methods as required.
  • Decision Gate D: Cleared dossiers for localization; established response engine and hearing preparation plan.
• Weeks 9–10: Country Tailoring and Submission Prep
  • Tailored NICE, G-BA/IQWiG, SMC, and HAS dossiers; finalized survival extrapolations and local inputs; translated and redacted materials; prepared hearing scripts and Q&A libraries.
  • Decision Gate E: Validated submission packages; scheduled filings; aligned pricing/MEA guardrails with negotiation plans.
• Weeks 11–12: Response Engine, Training, and Handoff
  • Launched response engine; rehearsed hearings; trained affiliates on models and narratives; finalized governance for updates and dossier refreshes.
  • Decision Gate F: Authorized submissions; set cadence for policy monitoring, evidence generation, and dossier maintenance.
• Weeks 13–14 (optional): Stress Tests and JCA Readiness
  • Stress-tested model and narrative under alternative comparators and price corridors; prepared a harmonization plan for EU Joint Clinical Assessment; refined risk register and mitigations.

Critical path items included comparator alignment (especially ZVT in Germany and NICE scoping), survival extrapolation and utility validation, model transparency and validation logs, early advice scheduling, translation/redaction throughput, and affiliate enablement for hearings and negotiations.

8) Deliverables

• Global HTA Strategy and Comparator Alignment Pack
  • HTA milestones, agency requirements, comparator matrix by country, value objectives and trade-offs, early advice plan, and governance charter.
• Evidence Compendium and Clinical Narrative Library
  • Consolidated clinical/HRQoL/HRU evidence, ITC/NMA outputs, survival extrapolation documentation, and country-ready narratives (NICE/G-BA/SMC/HAS formats).
• Global Economic Model and Country Adaptation Kits
  • Base CEM/PSM and BIM with assumption books, validation logs, sensitivity/scenario sets; country input libraries (tariffs, utilities, practice patterns) and adaptation guides.
• Global Value Dossier (GVD)
  • HTA Core Model-aligned dossier with country annexes; reference management and change log for affiliate use.
• AMCP Dossier and PIE Materials
  • US payer dossier, executive summary, BIM/CEM outputs, and PIE-compliant materials with version control.
• Country Submission Dossiers
  • NICE, G-BA AMNOG (Modules 1–5 as required), SMC, HAS packages with local inputs, translations/redactions, and alignment with pricing/MEA guardrails.
• Hearing and Response Playbook
  • Oral/written statements, Q&A library, figure/style guide, response engine SOPs, and rehearsal kits.
• Pricing and MEA Negotiation Briefs
  • Price–ICER simulator outputs, ERP risk assessment, contracting guardrails, and MEA design options with operational plans.
• Affiliate Enablement Toolkit
  • Training modules, model user guides, local data request templates, translation/redaction workflows, and submission checklists.
• Post-Approval HEOR/RWE Roadmap
  • Evidence generation plan, registry/claims partnerships, publication calendar, policy monitoring dashboard, and dossier refresh schedule.
• Executive Dashboard and Risk Register
  • Submission status, early advice outcomes, ICER/ASMR/additional benefit targets vs. corridors, MEA status, policy watch, and risk mitigation tracker; KPI dictionary with lineage.

9) Industry Insights

• Comparator choice is the keystone
  • HTAs assess value against appropriate local comparators: ZVT for G-BA, NICE scoping-selected options, HAS and SMC practice-based therapies. Misalignment drives questions and delayed or negative rulings; anchored ITC/NMA and transparent rationale are critical.
• Transparency and validation win credibility
  • Models and ITC/NMA with clear assumptions, sensitivity analyses, and validation logs outperform opaque approaches. Documented survival extrapolation choices and external validation increase trust with technical teams.
• NICE severity modifiers and evolving thresholds matter
  • Severity modifiers and equality considerations can shift acceptability bands. Early scoping and engagement with NICE improve alignment on endpoints and modeling choices.
• AMNOG requires granular subgroup logic
  • G-BA/IQWiG emphasize patient-relevant endpoints and subgroup analyses; benefit categories (major/considerable/minor/non-quantifiable) determine price negotiations. ZVT, subgroup justification, and hearing preparation are decisive.
• HAS ASMR is driven by clinical added value
  • SMR/ASMR outcomes hinge on comparator selection, magnitude/durability of effect, and quality of evidence. Early dialogue and planning for post-listing studies can improve sustainability.
• SMC favors concise, technically sound submissions
  • Clear clinical and economic narratives with transparent uncertainty handling and patient/clinician group alignment improve prospects; FAST-TRACK criteria and ultra-orphan pathways require bespoke strategies.
• EU Joint Clinical Assessment changes the game
  • EU HTA regulation phases in JCA, demanding consistent clinical evidence across Member States; dossier harmonization and early planning reduce divergence and workload.
• MEAs and data collection are mainstream
  • Outcome-based and data collection agreements increasingly condition access; early planning for outcome selection and data infrastructure speeds negotiation and execution.
• US payer expectations extend beyond FDA approval
  • AMCP dossiers, PIE, and credible BIM/CEM scenarios accelerate coverage; coding, routing, and distribution/HUB readiness determine uptake speed.
• What “good” looks like
  • A harmonized GVD and AMCP dossier; aligned comparators with robust ITC/NMA; validated global model with country kits; sequenced early advice and submissions; trained affiliates with response/hearing playbooks; pricing/MEA guardrails anchored to ICER targets; and a post-approval RWE plan for policy maintenance.
• Near-term watch points
  • Threshold changes (NICE), methodological preferences (IQWiG), HAS guidance updates, JCA implementation, biosimilar price dynamics, ERP spillovers, and data privacy constraints on RWE. Quarterly strategy refreshes and early dialogues maintain alignment with evolving HTA expectations.

Implications for clients we served included enabling Emerging Therapeutic Biotech to convert pivotal data into HTA-ready value stories; supporting Clinical-Stage Biotech to synchronize regulatory, HTA, and pricing plans for first-cycle decisions; equipping Commercial Biotech to maintain favorable positions through RWE and MEAs; guiding Platform Biotech to standardize GVD/AMCP and country submissions across partnered programs; and providing Biotech Investors & Incubators with diligence views on HTA risk, price corridors, and ICER/ASMR/additional benefit sensitivity across portfolios.